



**AWTTC**

All Wales Therapeutics & Toxicology Centre  
Canolfan Therapiwteg a Thocsicoleg Cymru Gyfan




**WAPSU**

Welsh Analytical Prescribing Support Unit  
Uned Cymorth Presgripsiynu Dadansoddol Cymru

# National Prescribing Indicators 2018–2019 Specifications



May 2018



This document has been prepared by the Welsh Analytical Prescribing Support Unit (WAPSU), part of the All Wales Therapeutics and Toxicology Centre (AWTTC).

Please direct any queries to AWTTC:

All Wales Therapeutics and Toxicology Centre (AWTTC)  
University Hospital Llandough  
Penlan Road  
Llandough  
Vale of Glamorgan  
CF64 2XX

[awttc@wales.nhs.uk](mailto:awttc@wales.nhs.uk)  
029 2071 6900

This document should be cited as:  
Welsh Analytical Prescribing Support Unit, All Wales Therapeutics and Toxicology Centre. National Prescribing Indicators 2018–2019 Specifications. May 2018.

## INTRODUCTION

The [National Prescribing Indicators \(NPIs\) 2018–2019](#) were developed by the All Wales Prescribing Advisory Group (AWPAG), and underwent a period of consultation prior to their endorsement by the All Wales Medicines Strategy Group (AWMSG).

This supplementary document details the specifications of each NPI including data source, drug baskets and targets/thresholds\* as appropriate for the NPIs 2018–2019.

For each NPI with a threshold, this is set at the 75<sup>th</sup> percentile (i.e. the prescribing rate of the best performing 25% of practices), for the quarter ending 31<sup>st</sup> December 2017. Unless otherwise stated, the threshold is based on prescribing data for all general practices in Wales.

For those NPIs with a drug basket, the British National Formulary (BNF) medicine name and associated BNF coding structure within the Comparative Analysis System for Prescribing Audit (CASPAs) have been listed for each medicine.

It should be noted that some of the drug baskets may contain medicines that have been discontinued. These are kept in the drug baskets for purposes of historic reporting and also to identify any prescribing of discontinued medicines.

The NPI values will be produced quarterly: for quarters ending June 2018, September 2018, December 2018 and March 2019.

## 1.0 SAFETY INDICATORS

### 1.1 PRESCRIBING SAFETY INDICATORS

**Data source:** Audit+

**Unit of measure:**

1. Number of patients with a peptic ulcer who have been prescribed NSAIDs without a PPI as a percentage of all patients.
2. Number of patients with asthma who have been prescribed a beta-blocker as a percentage of all patients.
3. Number of patients with concurrent prescriptions of verapamil and a beta-blocker as a percentage of all patients.
4. Number of female patients with a past medical history of venous or arterial thrombosis who have been prescribed combined hormonal contraceptives, as a percentage of all female patients.
5. Number of female patients with a current prescription of oestrogen-only hormone replacement therapy without any hysterectomy READ/SNOMED codes, as a percentage of all female patients.
6. Number of patients with concurrent prescriptions of warfarin and an oral NSAID as a percentage of all patients.
7. Number of patients under 12 with a current prescription of aspirin, unless due to a specialist recommendation, as a percentage of all patients.
8. Number of patients aged 65 years or over prescribed an NSAID plus aspirin and/or clopidogrel but without gastroprotection (PPI or H<sub>2</sub> receptor antagonist), as a percentage of all patients aged 65 years or over.
9. Number of patients aged 65 years or over prescribed an antipsychotic, as a percentage of all patients aged 65 years or over.

---

\* Targets for 4C antimicrobials are practice specific and will be made available via SPIRA.

10. Number of patients aged 75 and over with an Anticholinergic Effect on Cognition (AEC) score of 3 or more for items on active repeat, as a percentage of all patients aged 75 and over.
11. Number of patients on the CKD register (CKD stage 3–5) who have received a repeat prescription for an NSAID within the last 3 months, as a percentage of all patients on the CKD register.
12. Number of patients who are not on the CKD register but have an eGFR of < 59 ml/min and have received a repeat prescription for an NSAID within the last 3 months, as a percentage of all patients who are not on the CKD register but have an eGFR of < 59 ml/min.

**Target for 2018–2019:** No target set.

## 1.2 HYPNOTICS AND ANXIOLYTICS

**Data source:** NHS Wales Shared Services Partnership (NWSSP)

**Unit of measure:** Average daily quantities (ADQs) per 1,000 specific therapeutic group age–sex related prescribing units (STAR-PUs) of hypnotics and anxiolytics.

**Target for 2018–2019:** Maintain performance levels within the lower quartile (threshold: 2,005 ADQs per 1,000 STAR-PUs), or show a reduction towards the quartile below.

### **Numerator**

ADQs of a user-defined group (UDG) of hypnotic and anxiolytic drugs

BNF Code	BNF Level	BNF Name
0401010L0	BNF chemical	Flurazepam Hydrochloride
0401010N0	BNF chemical	Loprazolam Mesilate
0401010P0	BNF chemical	Lormetazepam
0401010R0	BNF chemical	Nitrazepam
0401010T0	BNF chemical	Temazepam
0401010W0	BNF chemical	Zaleplon
0401010Y0	BNF chemical	Zolpidem Tartrate
0401010Z0	BNF chemical	Zopiclone
0401020D0	BNF chemical	Chlordiazepoxide
0401020E0	BNF chemical	Chlordiazepoxide Hydrochloride
0401020K0	BNF chemical	Diazepam
0401020P0	BNF chemical	Lorazepam
0401020T0	BNF chemical	Oxazepam

### **Denominator**

1,000 STAR-PUs

## 1.3 ANALGESICS

### 1.3.1 TRAMADOL

**Data source:** NWSSP

**Unit of measure:** Defined daily doses (DDD) of tramadol and tramadol-containing products per 1,000 patients.

**Target for 2018–2019:** Maintain performance levels within lower quartile (threshold: 397 DDDs per 1,000 patients), or show a reduction towards the quartile below.

**Numerator**

DDDs of tramadol

BNF Code	BNF Level	BNF Name
040702040	BNF chemical	Tramadol Hydrochloride

**Denominator**

1,000 patients

### 1.3.2 OPIOID PATCHES

**Data source:** NWSSP

**Unit of measure:** Opioid patch items as a percentage of all opioid prescribing.

**Target for 2018–2019:** Maintain performance levels with lower quartile (threshold: 7.51%), or show a reduction towards the quartile below.

**Numerator**

Items of opioid patches

BNF Code	BNF Level	BNF Name
0407020A0AAAEAE	BNF preparation	Fentanyl_Transdermal Patch 25mcg/hr
0407020A0AAAFAP	BNF preparation	Fentanyl_Transdermal Patch 50mcg/hr
0407020A0AAAGAG	BNF preparation	Fentanyl_Transdermal Patch 75mcg/hr
0407020A0AAAHAAH	BNF preparation	Fentanyl_Transdermal Patch 100mcg/hr
0407020A0AAAUAU	BNF preparation	Fentanyl_Transdermal Patch 12mcg/hr
0407020A0AABWBW	BNF preparation	Fentanyl_Transdermal Patch 37.5mcg/hr
0407020A0BB	BNF product	Durogesic
0407020A0BD	BNF product	Tilofyl
0407020A0BE	BNF product	Matrifen
0407020A0BF	BNF product	Mezolar
0407020A0BG	BNF product	Fentalis
0407020A0BH	BNF product	Osmach
0407020A0BL	BNF product	Osmanil
0407020A0BM	BNF product	Victanyl
0407020A0BQ	BNF product	Fencino
0407020A0BR	BNF product	Opiodur
0407020A0BU	BNF product	Mylafent
0407020A0BV	BNF product	Yemex
0407020B0AAAEAE	BNF preparation	Buprenorphine_Patch 35mcg/hr (96hr)
0407020B0AAAFAP	BNF preparation	Buprenorphine_Patch 52.5mcg/hr (96hr)
0407020B0AAAGAG	BNF preparation	Buprenorphine_Patch 70mcg/hr (96hr)
0407020B0AAAHAAH	BNF preparation	Buprenorphine_Patch 5mcg/hr (7day)
0407020B0AAAIAI	BNF preparation	Buprenorphine_Patch 10mcg/hr (7day)
0407020B0AAAJAJ	BNF preparation	Buprenorphine_Patch 20mcg/hr (7day)
0407020B0AAAKAK	BNF preparation	Buprenorphine_Patch 15mcg/hr (7day)
0407020B0BD	BNF product	Transtec
0407020B0BE	BNF product	Butrans
0407020B0BG	BNF product	Hapoctasin
0407020B0BH	BNF product	Butec

0407020B0BI	BNF product	Bupeaze
0407020B0BK	BNF product	Reletrans
0407020B0BL	BNF product	Panitaz
0407020B0BM	BNF product	Sevodyne
0407020B0BN	BNF product	Buplast
0407020B0BP	BNF product	Relevtec
0407020B0BR	BNF product	Busiete

### ***Denominator***

All opioid items

BNF Code	BNF Level	BNF Name
0407020	BNF sub section	Opioid Analgesics

## **1.3.3 GABAPENTIN AND PREGABALIN**

**Data source:** NWSSP

**Unit of measure:** DDDs of gabapentin and pregabalin products per 1,000 patients.

**Target for 2018–2019:** Maintain performance levels within lower quartile (threshold: 1,055 DDDs per 1,000 patients), or show a reduction towards the quartile below.

### ***Numerator***

DDDs of gabapentin and pregabalin

BNF Code	BNF Level	BNF Name
0408010G0	BNF chemical	Gabapentin
0408010AE	BNF chemical	Pregabalin
0407030AA	BNF chemical	Pregabalin

### ***Denominator***

1,000 patients

## **1.4 YELLOW CARDS**

**Data source:** Medicines and Healthcare products Regulatory Agency (MHRA)

**Unit of measure:** Number of Yellow Cards submitted, per GP practice, per health board and per hospital.

### ***Target for 2018–2019:***

- Target for GP practices: to submit one Yellow Card per 2,000 practice population.
- Target for health boards:
  - Submit in excess of one Yellow Card per 2,000 health board population.
  - Demonstrate a 20%, or greater, increase from baseline, for Yellow Cards submitted by secondary care.
  - Demonstrate a 50%, or greater, increase from baseline, for Yellow Cards submitted by members of the public.

## 2.0 ANTIMICROBIAL STEWARDSHIP INDICATORS

### 2.1 TOTAL ANTIBACTERIAL ITEMS

**Data source:** NWSSP

**Unit of measure:** Total antibacterial items per 1,000 STAR-PUs.

**Target for 2018–2019:** Health board target: A reduction of 5% against a baseline of data from April 2016–March 2017.

	Quarter ending June		Quarter ending September		Quarter ending December		Quarter ending March	
	2016 data	2018 target	2016 data	2018 target	2016 data	2018 target	2017 data	2019 target
ABMU	327.5	311.1	309.1	293.6	356.1	338.3	348.1	330.7
Aneurin Bevan	309.4	293.9	290.0	275.5	337.9	321.0	339.0	322.0
Betsi Cadwaladr	309.8	294.3	299.1	284.1	344.3	327.1	335.1	318.3
Cardiff and Vale	281.7	267.6	273.0	259.4	314.7	299.0	311.1	295.5
Cwm Taf	325.5	309.3	317.8	301.9	371.2	352.6	371.8	353.2
Hywel Dda	309.1	293.7	300.9	285.8	344.6	327.4	345.3	328.1
Powys	261.6	248.5	248.5	236.1	281.6	267.5	284.4	270.2
Wales	307.6	292.3	294.8	280.0	340.3	323.3	336.8	319.9

#### Numerator

All antibacterial items

BNF Code	BNF Level	BNF Name
0501	BNF section	Antibacterial drugs

#### Denominator

1,000 STAR-PUs

### 2.2 4C ANTIMICROBIALS

**Data source:** NWSSP

**Unit of measure:** Co-amoxiclav, cephalosporin, fluoroquinolone and clindamycin items combined, per 1,000 patients.

**Target for 2018–2019:** A proportional reduction of 10% against a baseline of data from April 2016–March 2017.

#### Numerator

Items of co-amoxiclav, cephalosporins, fluoroquinolones and clindamycin

BNF Code	BNF Level	BNF Name
0501013K0	BNF chemical	Co-Amoxiclav (amoxicillin/clavul Acid)
0501020B0	BNF chemical	Cefaclor
0501020D0	BNF chemical	Cefadroxil
0501020E0	BNF chemical	Cefixime

0501020F0	BNF chemical	Cefotaxime sodium
0501020I0	BNF chemical	Cefpodoxime
0501020K0	BNF chemical	Ceftriaxone sodium
0501020L0	BNF chemical	Ceftazidime Pentahydrate
0501020P0	BNF chemical	Cefuroxime sodium
0501020Q0	BNF chemical	Cefuroxime axetil
0501020R0	BNF chemical	Cefalexin
0501020W0	BNF chemical	Cefradine
0501021	BNF sub section	Cephalosporins
0501120	BNF subsection	Quinolones
0501060	BNF sub section	Clindamycin

### **Denominator**

1,000 patients

**Unit of measure:** Co-amoxiclav, cephalosporin, fluoroquinolone and clindamycin items combined, as a percentage of total antibacterial items.

**Target for 2018–2019:** Absolute measure  $\leq 7\%$  or a proportional reduction of 10% against a baseline of data from April 2016–March 2017 (quarterly target).

### **Numerator**

Items of co-amoxiclav, cephalosporins, fluoroquinolones and clindamycin

BNF Code	BNF Level	BNF Name
0501013K0	BNF chemical	Co-Amoxiclav (amoxicillin/clavul Acid)
0501020B0	BNF chemical	Cefaclor
0501020D0	BNF chemical	Cefadroxil
0501020E0	BNF chemical	Cefixime
0501020F0	BNF chemical	Cefotaxime sodium
0501020I0	BNF chemical	Cefpodoxime
0501020K0	BNF chemical	Ceftriaxone sodium
0501020L0	BNF chemical	Ceftazidime Pentahydrate
0501020P0	BNF chemical	Cefuroxime sodium
0501020Q0	BNF chemical	Cefuroxime axetil
0501020R0	BNF chemical	Cefalexin
0501020W0	BNF chemical	Cefradine
0501021	BNF sub section	Cephalosporins
0501120	BNF subsection	Quinolones
0501060	BNF sub section	Clindamycin

### **Denominator**

All antibacterial items

BNF Code	BNF Level	BNF Name
0501	BNF section	Antibacterial drugs

## **2.3 PROPHYLACTIC ANTIBIOTICS IN COLORECTAL SURGERY**

**Data source:** Data collected and submitted by antimicrobial pharmacists

**Unit of measure:** Proportion of elective colorectal patients receiving a single dose antimicrobial for surgical prophylaxis.

**Target for 2018–2019:** Absolute measure  $\geq 90\%$  or a proportional increase of 20% against performance for 2017–2018.

### 3.0 EFFICIENCY INDICATORS

#### 3.1 PROTON PUMP INHIBITORS

**Data source:** NWSSP

**Unit of measure:** Proton pump inhibitor (PPI) DDDs per 1,000 prescribing units (PUs).

**Target for 2018–2019:** Maintain performance levels within the lower quartile (threshold: 6,062 DDDs per 1,000 PUs), or show a reduction towards the quartile below.

**Numerator**

DDDs of PPIs

BNF Code	BNF Level	BNF Name
0103050	BNF sub section	Proton Pump Inhibitors

**Denominator**

1,000 PUs

#### 3.2 BIOSIMILARS

**Data source:** NWSSP and Medusa

**Unit of measure:** Quantity of biosimilar medicines prescribed as a percentage of total 'reference' product plus biosimilar.

**Target for 2018–2019:** Increase the appropriate use of cost-effective biological medicines, including biosimilar medicines.

Infliximab

**Numerator**

BNF Code	BNF Level	BNF Name
Inflectra (infliximab biosimilar) is not currently listed in CASPA		

**Denominator**

BNF Code	BNF Level	BNF Name
0105000T0	BNF chemical	Infliximab

Etanercept

**Numerator**

BNF Code	BNF Level	BNF Name
Benepali, Erelzi (etanercept biosimilars) are not currently listed in CASPA		

**Denominator**

BNF Code	BNF Level	BNF Name
1001030D0	BNF chemical	Etanercept

Rituximab

**Numerator**

BNF Code	BNF Level	BNF Name
Truxima (rituximab biosimilar) is not currently listed in CASPA		

**Denominator**

BNF Code	BNF Level	BNF Name
0802040V0	BNF chemical	Rituximab

**Insulin glargine****Numerator**

BNF Code	BNF Level	BNF Name
0601012V0BD	BNF product	Abasaglar

**Denominator**

BNF Code	BNF Level	BNF Name
0601012V0	BNF chemical	Insulin Glargine

For secondary care data the same item names are utilised from the Medusa data warehouse. However, it is essential that the brand name of the biosimilar medicine being supplied is clearly described to facilitate the data extraction to the Medusa data warehouse. Where 'home' appears within the description name this will be assumed to imply the supply is through Homecare delivery.

**3.3 LONG-ACTING INSULIN ANALOGUES**

**Data source:** NWSSP and Medusa

**Unit of measure:** Items/number of long-acting insulin analogues expressed as a percentage of total insulin prescribed.

**Target for 2018–2019:** Reduce prescribing of long-acting insulin analogues and achieve prescribing levels below the Welsh average.

**Numerator**

BNF Code	BNF Level	BNF Name
060102Z0	BNF chemical	Insulin Degludec
0601012AA	BNF chemical	Insulin Degludec and liraglutide
0601012X0	BNF chemical	Insulin Detemir
0601012V0	BNF chemical	Insulin Glargine
0601012G0	BNF chemical	Insulin Zinc suspension
0601012L0	BNF chemical	Insulin Zinc suspension (Amorphous)
0601012N0	BNF chemical	Insulin Zinc suspension (Crystalline)
0601012U0	BNF chemical	Protamine Zinc Insulin

**Denominator**

BNF Code	BNF Level	BNF Name
060102Z0	BNF chemical	Insulin Degludec
0601012AA	BNF chemical	Insulin Degludec and liraglutide
0601012X0	BNF chemical	Insulin Detemir
0601012V0	BNF chemical	Insulin Glargine
0601012G0	BNF chemical	Insulin Zinc suspension
0601012L0	BNF chemical	Insulin Zinc suspension (Amorphous)
0601012N0	BNF chemical	Insulin Zinc suspension (Crystalline)
0601012U0	BNF chemical	Protamine Zinc Insulin
0601012S0	BNF chemical	Isophane Insulin

For secondary care data the same item names are utilised from the Medusa data warehouse.